Accès gratuit
Numéro
Med Sci (Paris)
Volume 21, Numéro 3, Mars 2005
Page(s) 253 - 260
Section M/S revues
DOI https://doi.org/10.1051/medsci/2005213253
Publié en ligne 15 mars 2005
  1. Nilsen TW. The spliceosome : the most complex macromolecular machine in the cell ? BioEssays 2003; 25 : 1147–9.
  2. Caceres JF, Kornblihtt AR. Alternative splicing : multiple control mechanisms and involvement in human disease. Trends Genet 2002; 18 : 186–93.
  3. Faustino NA, Cooper TA. Pre-mRNA splicing and human disease. Genes Dev 2003; 17 : 419–37.
  4. Nissim-Rafinia M, Kerem B. Splicing regulation as a potential genetic modifier. Trends Genet 2002; 18 : 123–7.
  5. Black DL. Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem 2003; 72 : 291–336.
  6. Modrek B, Resch A, Grasso C, Lee C. Genome-wide detection of alternative splicing in expressed sequences of human genes. Nucleic Acids Res 2001; 29 : 2850–9.
  7. Hanke J, Brett D, Zastrow I, et al. Alternative splicing of human genes : more the rule than the exception ? Trends Genet 1999; 15 : 389–90.
  8. Modrek B, Lee C. A genomic view of alternative splicing. Nat Genet 2002; 30 : 13–9.
  9. Nagy E, Maquat LE. A rule for termination-codon position within intron-containing genes : when nonsense affects RNA abundance. Trends Biochem Sci 1998; 23 : 198–9.
  10. Proudfoot N. Connecting transcription to messenger RNA processing. Trends Biochem Sci 2000; 25 : 290–3.
  11. Logette E, Wotawa A, Solier S, et al. The human caspase-2 gene : alternative promoters, pre-mRNA splicing and AUG usage direct isoform-specific expression. Oncogene 2003; 22 : 935–46.
  12. Cartegni L, Chew SL, Krainer AR. Listening to silence and understanding nonsense : exonic mutations that affect splicing. Nat Rev Genet 2002; 3 : 285–98.
  13. Brinkman BM. Splice variants as cancer biomarkers Clin Biochem 2004; 37 : 584–94.
  14. Garcia-Blanco MA, Baraniak AP, Lasda EL. Alternative splicing in disease and therapy. Nat Biotechnol 2004; 22 : 535–46.
  15. Roberts GC, Smith CW. Alternative splicing : combinatorial output from the genome. Curr Opin Chem Biol 2002; 6 : 375–83.
  16. Yeakley JM, Fan JB, Doucet D, et al. Profiling alternative splicing on fiber-optic arrays. Nat Biotechnol 2002; 20 : 353–8.
  17. Zhu J, Shendure J, Mitra RD, Church GM. Single molecule profiling of alternative pre-mRNA splicing. Science 2003; 301 : 836–8.
  18. Jin P, Fu GK, Wilson AD, et al. PCR isolation and cloning of novel splice variant mRNAs from known drug target genes. Genomics 2004; 83 : 566–71.
  19. Lareau LF, Green RE, Bhatnagar RS, Brenner SE. The evolving roles of alternative splicing. Curr Opin Struct Biol 2004; 14 : 273–82.
  20. Stickeler E, Kittrell F, Medina D, Berget SM. Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis. Oncogene 1999; 18 : 3574–8.
  21. Yamaguchi F, Saya H, Bruner JM, Morrison RS. Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas. Proc Natl Acad Sci USA 1994; 91 : 484–8.
  22. Sneath RJ, Mangham DC. The normal structure and function of CD44 and its role in neoplasia. Mol Pathol 1998; 51 : 191–200.
  23. Thakur S, Zhang HB, Peng Y, et al. Localization of BRCA1 and a splice variant identifies the nuclear localization signal. Mol Cell Biol 1997; 17 : 444–52.
  24. Nissim-Rafinia M, Kerem B. Splicing regulation as a potential genetic modifier. Trends Genet 2002; 18 : 123–7.
  25. Nissim-Rafinia M, Chiba-Falek O, Sharon G, et al. Cellular and viral splicing factors can modify the splicing pattern of CFTR transcripts carrying splicing mutations. Hum Mol Genet 2000; 9 : 1771–8.
  26. Hofmann Y, Lorson CL, Stamm S, et al. Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2). Proc Natl Acad Sci USA 2000; 97 : 9618–23.
  27. Wu JY, Tang H, Havlioglu N. Alternative pre-mRNA splicing and regulation of programmed cell death. Prog Mol Subcell Biol 2003; 31 : 153–85.
  28. Pilch B, Allemand E, Facompre M, et al. Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506. Cancer Res 2001; 61 : 6876–84.
  29. Cartegni L, Krainer AR. Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat Struct Biol 2003; 10 : 120–5.
  30. Chang JG, Hsieh-Li HM, Jong YJ, et al. Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci USA 2001; 98 : 9808–13.
  31. Andreassi C, Jarecki J, Zhou J, et al. Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum Mol Genet 2001; 10 : 2841–9.
  32. Wotawa A, Solier S, Logette E, et al. Differential influence of etoposide on two caspase-2 mRNA isoforms in leukemic cells. Cancer Lett 2002; 185 : 181–9.
  33. Solier S, Lansiaux A, Logette E, et al. Topoisomerase I and II inhibitors control caspase-2 pre-messenger RNA splicing in human cells. Mol Cancer Res 2004; 2 : 53–61.
  34. Aubœuf D, Honig A, Berget SM, O’Malley BW. Coordinate regulation of transcription and splicing by steroid receptor coregulators. Science 2002; 298 : 416–9.
  35. Lu QL, Mann CJ, Lou F, et al. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med 2003; 9 : 1009–14.
  36. Goyenvalle A, Vulin A, Fougerousse F, et al. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 2004; 306 : 1746–9.
  37. Skordis LA, Dunckley MG, Yue B, et al. Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc Natl Acad Sci USA 2003; 100 : 4114–9.
  38. Cartegni L, Krainer AR. Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat Struct Biol 2003; 10 : 120–5.
  39. Villemaire J, Dion I, Elela SA, Chabot B. Reprogramming alternative pre-messenger RNA splicing through the use of protein-binding antisense oligonucleotides. J Biol Chem 2003; 278 : 50031–9.
  40. Celotto AM, Graveley BR. Exon-specific RNAi : a tool for dissecting the functional relevance of alternative splicing. RNA 2002; 8 : 718–24.
  41. Chao H, Mansfield SG, Bartel RC, et al. Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing. Nat Med 2003; 9 : 1015–9.
  42. Rogers CS, Vanoye CG, Sullenger BA, George AL Jr. Functional repair of a mutant chloride channel using a trans-splicing ribozyme. J Clin Invest 2002; 110 : 1783–9.
  43. Deidda G, Rossi N, Tocchini-Valentini GP. An archaeal endoribonuclease catalyzes cis- and trans- nonspliceosomal splicing in mouse cells. Nat Biotechnol 2003; 21 : 1499–504.
  44. Burge CB, Tuschl T, Sharp PA. Splicing of precursors to mRNAs by the spliceosomes. In : Gesteland RF, Cech TR, Atkins JF, eds. The RNA world II. Cold Spring Harbor-New York : Cold Spring Harbor Laboratory Press, 1999 : 525–60.
  45. Sanford JR, Bruzick JP. Developmental regulation of SR protein phosphorylation and activity. Genes Dev 1999; 13 : 1513–8.
  46. Mistelli T, Spector DL. The cellular organization of gene expression. Curr Opin Cell Biol 1998; 10 : 323–31.
  47. Murray MV. Role of phosphorylation in pre-mRNA splicing. Front Horm Res 1999; 25 : 83–100.
  48. Dreyfuss G, Matunis MJ, Piñol-Roma S, Burd CG. HnRNP proteins and the biogenesis of mRNA. Annu Rev Biochem 1993; 63 : 289–321.
  49. Sazani P, Kole R. Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. J Clin Invest 2003; 112 : 481–6.
  50. Mann CJ, Honeyman K, Cheng AJ, et al. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci USA 2001; 98 : 42–7.
  51. Mercatante DR, Mohler JL, Kole R. Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents. J Biol Chem 2002; 277 : 49374–82.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.